AUSTIN, Texas--(BUSINESS WIRE)--Triumvira Immunologics, Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple types of cancers, today announced that it will present a company overview at the 4th Annual Immuno-Oncology Business Development & Licensing and Investment Forum (IOBDLI), in Chicago on June 1, and attend the 2018 BIO International Convention in Boston on June 4-5.
At the IOBDLI Forum, Triumvira Scientific Founder and Acting Chief Scientific Officer, Dr. Jonathan Bramson, will provide an overview of the company’s T Cell-Antigen Coupler (TAC) technology, as well as updates on Triumvira’s lead drug, CD19-TAC01, which is targeted to enter clinical development in H1 2019 for the treatment of patients with CD19 positive B-cell malignancies. Dr. Bramson will be presenting at 3:20 p.m. CT on June 1.
At BIO International, President and Chief Executive Officer, Dr. Paul Lammers will be available for private meetings during the day on June 4-5 to discuss potential collaboration and licensing opportunities for the Company’s novel immuno-oncology platform T Cell-Antigen Coupler (TAC).
About the IOBDLI Forum
The 4th Annual Immuno-Oncology BD&L and Investment Forum, a by-invitation-only event to be held at the Waldorf Astoria Chicago Hotel, is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment.
About the 2018 BIO International Convention
The BIO International Convention, to be held at the Boston Convention and Exhibition Center, is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
About Triumvira Immunologics
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, with our research facilities in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to email@example.com.